GlassScriptPhysician profile
Christopher Allen Pate
NPI 1740736263
$2,828.82
in general payments reported to CMS, 2019-2025
23 companies · $704 in 2025
The $704 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $490 · 2023: $963 · 2024: $557 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $471.64 | 2023-2025 | Orgovyx, Gemtesa |
| Antares Pharma, INC. | $445.84 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Endo Pharmaceuticals INC. | $337.10 | 2022-2023 | Xiaflex, Aveed |
| Astellas Pharma US INC | $308.96 | 2021-2025 | Xtandi, Veozah, Myrbetriq |
| Abbvie INC. | $182.98 | 2021-2025 | |
| Tolmar, INC. | $179.30 | 2023-2025 | Jatenzo, Eligard |
| Pfizer INC. | $126.13 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $106.22 | 2023-2025 | Prolaris |
| Medtronic, INC. | $104.17 | 2023-2025 | Interstim, Altaviva, Linq II |
| Endo USA, INC. | $73.21 | 2024-2025 | Xiaflex |
| Halozyme INC | $64.72 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.83 | 2022-2023 | |
| Coloplast Corp | $51.01 | 2022-2023 | Titan, Speedicath |
| Myovant Sciences INC. | $48.77 | 2022 | |
| Ferring Pharmaceuticals INC. | $42.12 | 2025 | Adstiladrin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $41.13 | 2025 | |
| Axonics, INC. | $37.76 | 2024 | Axonics |
| Urovant Sciences INC | $36.26 | 2022 | |
| Urogen Pharma, INC. | $31.82 | 2025 | |
| Procept Biorobotics Corporation | $28.90 | 2023 | Aquabeam Robotic System |
| 180 Medical, INC. | $24.89 | 2024 | Gentlecath Glide |
| Teleflex LLC | $23.57 | 2025 | Urolift |
| Travere Therapeutics, INC. | $2.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.